Advertisement

Psychopharmacology

, Volume 169, Issue 3–4, pp 308–313 | Cite as

Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation

  • Lee Zuckerman
  • Ina WeinerEmail author
Original Investigation

Abstract

Rationale

There is evidence pointing to an association between prenatal exposure to infection and increased liability to schizophrenia, and it has been suggested that the maternal immune response, in particular, the release of pro-inflammatory cytokines, may interfere with normal fetal brain development. Impaired capacity to ignore irrelevant stimuli is considered one of the central deficits in schizophrenia, and is manifested, among others, in disrupted latent inhibition (LI).

Objectives

To test the effects of prenatal immune activation on LI in juvenile and adult offspring.

Methods

Pregnant rats were injected with the synthetic cytokine releaser polyriboinosinic-polyribocytidilic acid (poly I:C, 4 mg/kg) on gestational day 15. LI was assessed in 35-day and 3-month-old offspring using a thirst motivated conditioned emotional response procedure.

Results

Consistent with the characteristic maturational delay of schizophrenia, prenatal immune activation did not affect LI in the juvenile offspring but led to a post-pubertal emergence of LI disruption. In addition, pronounced alterations in hippocampal morphology resembling those found in schizophrenia, were evident in the adult offspring.

Conclusions

These results support the hypothesis that immune activation during pregnancy may lead to long-term abnormalities mimicking those observed in schizophrenia.

Keywords

Latent inhibition Poly I:C Cytokines Schizophrenia Hippocampus Neurodevelopment 

Notes

Acknowledgements

We gratefully acknowledge the help of Drs. Raya Eilam and Tamar Kadar in the histological assessment. This research was partly supported by Adams Super-Center for Brain Studies, Tel-Aviv University, and the Israel Foundation Trustees award to L.Z.

References

  1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761–767PubMedGoogle Scholar
  2. Adams W, Kendell RE, Hare EH, Munk-Jorgensen P (1993) Epidemiological evidence that maternal influenza contributes to the aetiology of schizophrenia. An analysis of Scottish, English, and Danish data. Br J Psychiatry 163:522–534PubMedGoogle Scholar
  3. Baruch I, Hemsley D, Gray JA (1988) Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 176:598–606PubMedGoogle Scholar
  4. Bayer SA, Altman J (1991) Neocortical development. Raven Press, New YorkGoogle Scholar
  5. Borrell J, Vela JM, Arevalo-Martin A, Molina-Holgado E, Guaza C (2002) Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology 26:204–215CrossRefPubMedGoogle Scholar
  6. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569–2574PubMedGoogle Scholar
  7. Doukas J, Cutler AH, Mordes JP (1994) Polyinosinic:polycytidylic acid is a potent activator of endothelial cells. Am J Pathol 145:137–147PubMedGoogle Scholar
  8. Engel JA, Zhang J, Bergstrom T, Conradi N, Forkstam C, Liljeroth A, Svensson L (2000) Neonatal herpes simplex virus type 1 brain infection affects the development of sensorimotor gating in rats. Brain Res 863:233–240CrossRefPubMedGoogle Scholar
  9. Fatemi SH, Emamian ES, Kist D, Sidwell RW, Nakajima K, Akhter P, Shier A, Sheikh S, Bailey K (1999) Defective corticogenesis and reduction in Reelin immunoreactivity in cortex and hippocampus of prenatally infected neonatal mice. Mol Psychiatry 4:145–154CrossRefPubMedGoogle Scholar
  10. Gilmore JH, Jarskog LF (1997) Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia [letter]. Schizophr Res 24:365–367CrossRefPubMedGoogle Scholar
  11. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD (1991) The neuropsychology of schizophrenia. Behav Brain Sci 14:1–84Google Scholar
  12. Gray NS, Hemsley DR, Gray JA (1992) Abolition of latent inhibition in acute, but not chronic schizophrenics. Neurol Psychiatr Brain Res 1:83–89Google Scholar
  13. Gray NS, Pilowsky LS, Gray JA, Kerwin RW (1995) Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr Res 17:95–107PubMedGoogle Scholar
  14. Grecksch G, Bernstein HG, Becker A, Hollt V, Bogerts B (1999) Disruption of latent inhibition in rats with postnatal hippocampal lesions. Neuropsychopharmacology 20:525–532CrossRefPubMedGoogle Scholar
  15. Harrison PJ (1999) The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122:593–624CrossRefPubMedGoogle Scholar
  16. Jarskog LF, Xiao H, Wilkie MB, Lauder JM, Gilmore JH (1997) Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int J Dev Neurosci 15:711–716CrossRefPubMedGoogle Scholar
  17. Jones PB, Rantakallio P, Hartikainen AL, Isohanni M, Sipila P (1998) Schizophrenia as a long-term outcome of pregnancy, delivery, and perinatal complications: a 28-year follow-up of the 1966 north Finland general population birth cohort. Am J Psychiatry 155:355–364PubMedGoogle Scholar
  18. Kirch DG (1993) Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr Bull 19:355–370PubMedGoogle Scholar
  19. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computerized tomography imaging of amphetamine- induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235–9240PubMedGoogle Scholar
  20. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R (1999) Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46:56–72PubMedGoogle Scholar
  21. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J (2001) The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50:884–897CrossRefPubMedGoogle Scholar
  22. Lipska BK, Weinberger DR (2000) To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23:223–239PubMedGoogle Scholar
  23. Lipska BK, Jaskiw GE, Weinberger DR (1993) Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage—a potential animal model of schizophrenia. Neuropsychopharmacology 9:67–75PubMedGoogle Scholar
  24. Marx CE, Jarskog LF, Lauder JM, Lieberman JA, Gilmore JH (2001) Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia. Biol Psychiatry 50:743–749CrossRefPubMedGoogle Scholar
  25. McGue M, Gottesman, II (1991) The genetic epidemiology of schizophrenia and the design of linkage studies. Eur Arch Psychiatr Clin Neurosci 240:174–181Google Scholar
  26. Mednick SA, Machon RA, Huttunen MO, Bonett D (1988) Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 45:189–192PubMedGoogle Scholar
  27. Mednick SA, Huttunen MO, Machon RA (1994) Prenatal influenza infections and adult schizophrenia. Schizophr Bull 20:263–267PubMedGoogle Scholar
  28. Mehler MF, Kessler JA (1998) Cytokines in brain development and function. Adv Protein Chem 52:223–251PubMedGoogle Scholar
  29. Merrill JE (1992) Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological. Dev Neurosci 14:1–10PubMedGoogle Scholar
  30. Moser PC, Hitchcock JM, Lister S, Moran PM (2000) The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Rev 33:275–307PubMedGoogle Scholar
  31. Murray RM, Jones P, O'Callaghan E, Takei N, Sham P (1992) Genes, viruses and neurodevelopmental schizophrenia. J Psychiatr Res 26:225–235CrossRefPubMedGoogle Scholar
  32. Nawa H, Takahashi M, Patterson PH (2000) Cytokine and growth factor involvement in schizophrenia—support for the developmental model. Mol Psychiatry 5:594–603CrossRefPubMedGoogle Scholar
  33. O'Callaghan E, Sham P, Takei N, Glover G, Murray RM (1991) Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic. Lancet 337:1248–1250PubMedGoogle Scholar
  34. O'Callaghan E, Sham PC, Takei N, Murray G, Glover G, Hare EH, Murray RM (1994) The relationship of schizophrenic births to 16 infectious diseases. Br J Psychiatry 165:353–356PubMedGoogle Scholar
  35. Onstad S, Skre I, Torgersen S, Kringlen E (1991) Twin concordance for DSM-III-R schizophrenia. Acta Psychiatr Scand 83:395–401PubMedGoogle Scholar
  36. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic Press, San DiegoGoogle Scholar
  37. Pearce BD (2001) Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms. Mol Psychiatry 6:634–646CrossRefPubMedGoogle Scholar
  38. Pearce BD, Valadi NM, Po CL, Miller AH (2000) Viral infection of developing GABAergic neurons in a model of hippocampal disinhibition. Neuroreport 11:2433–2438PubMedGoogle Scholar
  39. Rascle C, Mazas O, Vaiva G, Tournant M, Raybois O, Goudemand M, Thomas P (2001) Clinical features of latent inhibition in schizophrenia. Schizophr Res 51:149–161CrossRefPubMedGoogle Scholar
  40. Rothschild DM, O'Grady M, Wecker L (1999) Neonatal cytomegalovirus exposure decreases prepulse inhibition in adult rats: implications for schizophrenia. J Neurosci Res 57:429–434CrossRefPubMedGoogle Scholar
  41. Rubin SA, Sylves P, Vogel M, Pletnikov M, Moran TH, Schwartz GJ, Carbone KM (1999) Borna disease virus-induced hippocampal dentate gyrus damage is associated with spatial learning and memory deficits. Brain Res Bull 48:23–30CrossRefPubMedGoogle Scholar
  42. Shalev U, Weiner I (2001) Gender-dependent differences in latent inhibition following prenatal stress and corticosterone administration. Behav Brain Res 126:57–63CrossRefPubMedGoogle Scholar
  43. Snell JC, Chernyshev O, Gilbert DL, Colton CA (1997) Polyribonucleotides induce nitric oxide production by human monocyte- derived macrophages. J Leukoc Biol 62:369–373PubMedGoogle Scholar
  44. Torrey EF, Rawlings R, Waldman IN (1988) Schizophrenic births and viral diseases in two states. Schizophr Res 1:73–77CrossRefPubMedGoogle Scholar
  45. Tsuang M (2000) Schizophrenia: genes and environment. Biol Psychiatry 47:210–20PubMedGoogle Scholar
  46. Tsuang MT, Stone WS, Faraone SV (2001) Genes, environment and schizophrenia. Br J Psychiatry 178: S18–S24PubMedGoogle Scholar
  47. Urakubo A, Jarskog LF, Lieberman JA, Gilmore JH (2001) Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. Schizophr Res 47:27–36CrossRefPubMedGoogle Scholar
  48. Weinberger DR (1995) From neuropathology to neurodevelopment. Lancet 346:552–557PubMedGoogle Scholar
  49. Weiner I (1990) Neural substrates of latent inhibition: the switching model. Psychol Bull 108:442–461CrossRefPubMedGoogle Scholar
  50. Weiner I (2000) The latent inhibition model of schizophrenia. In: Myslobodsky MS, Weiner I (eds) Contemporary issues in modeling psychopathology. Kluwer, Dordrecht, pp 197–230Google Scholar
  51. Weiner I (2001) Latent inhibition. In: Crawley JN, Gerfen CR, Rogawski MA, Sibley DR, Skolnick PS, Wray E (eds) Current protocols in neuroscience. Wiley, New YorkGoogle Scholar
  52. Weiner I (2003) The "two-headed" latent inhibition model of schizophrenia: modeling negative and positive symptoms and their treatment. Psychopharmacology DOI 10.1007/s00213-002-1313-xGoogle Scholar
  53. Weiner I, Feldon J (1997) The switching model of latent inhibition: an update of neural substrates. Behav Brain Res 88:11–25PubMedGoogle Scholar
  54. Weiner I, Feldon J, Ziv-Harris D (1987) Early handling and latent inhibition in the conditioned suppression paradigm. Dev Psychobiol 20:233–240Google Scholar
  55. Wright P, Gill M, Murray RM (1993) Schizophrenia: genetics and the maternal immune response to viral infection. Am J Med Genet 48:40–46PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Department of PsychologyTel Aviv UniversityTel AvivIsrael

Personalised recommendations